PhytoGaia presented clinical data at Vitafoods Asia 2026 on palm fruit-derived ingredient complexes, including a squalene and tocotrienol combination positioned for both oral supplementation and topical application, and a full-spectrum vitamin E complex studied for metabolic dysfunction-associated and alcohol-associated fatty liver disease. A separate randomized, placebo-controlled trial in dogs reported improvements in clinically assessed skin and coat measures. The showcase reflects a broader repositioning of healthy aging from a discrete product category into a formulation strategy applied across skin, liver and companion animal wellness.
Key Points
- Squalene-tocotrienol complex marketed for combined oral and topical use
- Vitamin E complex studied in metabolic and alcohol-related fatty liver
- Placebo-controlled canine trial reported skin and coat improvements
Longevity Analysis
Hepatic fat accumulation is one of the earliest reversible markers of metabolic deterioration, and interest in tocotrienols reflects a shift toward intervening before liver function declines measurably — the organ that clears metabolic byproducts also governs lipid handling, hormone processing and inflammatory tone. The dual oral-topical positioning of a single compound acknowledges that skin integrity and internal antioxidant status are not separable concerns. Claims of this kind warrant scrutiny of trial design, dosing and independence of the evidence before they inform practice, particularly where the data originate from the supplier.
Original published by Longevity.Technology, by Kyle Umipig.